2022
Infliximab Induction Lacks Efficacy and Increases BK Virus Infection in Deceased Donor Kidney Transplant Recipients: Results of the CTOT-19 Trial
Hricik D, Armstrong B, Alhamad T, Brennan D, Bromberg J, Bunnapradist S, Chandran S, Fairchild R, Foley D, Formica R, Gibson I, Kesler K, Kim SJ, Mannon R, Menon M, Newell K, Nickerson P, Odim J, Poggio E, Sung R, Shapiro R, Tinckam K, Vincenti F, Heeger P. Infliximab Induction Lacks Efficacy and Increases BK Virus Infection in Deceased Donor Kidney Transplant Recipients: Results of the CTOT-19 Trial. Journal Of The American Society Of Nephrology 2022, 34: 145-159. PMID: 36195441, PMCID: PMC10101585, DOI: 10.1681/asn.2022040454.Peer-Reviewed Original ResearchConceptsBiopsy-proven acute rejectionBK virus infectionIntravenous infliximabPrimary end pointTransplant recipientsKidney transplantVirus infectionDe novo donor-specific antibodiesDeceased donor kidney transplant recipientsRabbit anti-thymocyte globulin (rATG) inductionAnti-thymocyte globulin inductionCLINICAL TRIAL REGISTRY NAMEDonor kidney transplant recipientsNovo donor-specific antibodiesEnd pointPhase 2 clinical trialIFX induction therapyTRIAL REGISTRY NAMEDelayed graft functionDonor-specific antibodiesKidney transplant recipientsDeceased donor kidneysTNF-α productionPrimary transplant recipientsAcute rejectionDonor–Recipient Non-HLA Variants, Mismatches and Renal Allograft Outcomes: Evolving Paradigms
Jethwani P, Rao A, Bow L, Menon MC. Donor–Recipient Non-HLA Variants, Mismatches and Renal Allograft Outcomes: Evolving Paradigms. Frontiers In Immunology 2022, 13: 822353. PMID: 35432337, PMCID: PMC9012490, DOI: 10.3389/fimmu.2022.822353.Peer-Reviewed Original ResearchConceptsAllograft outcomesImportant recent dataRenal allograft outcomeAcute allograft rejectionKidney allograft outcomesDonor-recipient mismatchRecipient's immune systemNatural history studiesNon-HLA lociMajority of casesOrgan allocation processPolymorphic HLA genesAcute rejectionAllograft longevityAllograft lossMaintenance immunosuppressionTransplant outcomesAllograft rejectionImmune mechanismsPatient deathRecipient pairsDonor organsHLA variantsImmune systemOvert evidence
2019
A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection
Zhang W, Yi Z, Keung KL, Shang H, Wei C, Cravedi P, Sun Z, Xi C, Woytovich C, Farouk S, Huang W, Banu K, Gallon L, Magee CN, Najafian N, Samaniego M, Djamali A, Alexander SI, Rosales IA, Smith RN, Xiang J, Lerut E, Kuypers D, Naesens M, O'Connell PJ, Colvin R, Menon MC, Murphy B. A Peripheral Blood Gene Expression Signature to Diagnose Subclinical Acute Rejection. Journal Of The American Society Of Nephrology 2019, 30: 1481-1494. PMID: 31278196, PMCID: PMC6683710, DOI: 10.1681/asn.2018111098.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkersBiopsyFemaleGene Expression ProfilingGenomicsGraft RejectionGraft SurvivalHumansImmunosuppressive AgentsInflammationKaplan-Meier EstimateKidney Failure, ChronicKidney TransplantationMaleMiddle AgedOligonucleotide Array Sequence AnalysisProspective StudiesRisk FactorsSequence Analysis, RNAConceptsSubclinical acute rejectionKidney transplant recipientsAcute cellular rejectionAcute rejectionTransplant recipientsSurveillance biopsiesACR 3Graft functionHigh riskIndependent cohortPeripheral blood gene expression signaturesClinical acute rejectionFuture graft lossOngoing acute rejectionStable graft functionBlood gene expression signaturesCellular rejectionGraft lossGraft outcomeGraft survivalBorderline changesGene expression signaturesCox analysisHistologic featuresPeripheral blood
2017
Analysis of OPTN/UNOS registry suggests the number of HLA matches and not mismatches is a stronger independent predictor of kidney transplant survival
Yacoub R, Nadkarni GN, Cravedi P, He JC, Delaney VB, Kent R, Chauhan KN, Coca SG, Florman SS, Heeger PS, Murphy B, Menon MC. Analysis of OPTN/UNOS registry suggests the number of HLA matches and not mismatches is a stronger independent predictor of kidney transplant survival. Kidney International 2017, 93: 482-490. PMID: 28965746, DOI: 10.1016/j.kint.2017.07.016.Peer-Reviewed Original ResearchMeSH KeywordsDelayed Graft FunctionGraft RejectionGraft SurvivalHistocompatibilityHistocompatibility TestingHLA AntigensHumansKidney TransplantationPredictive Value of TestsProtective FactorsRegistriesRetrospective StudiesRisk FactorsTime FactorsTissue and Organ ProcurementTreatment OutcomeUnited StatesConceptsDelayed graft functionGraft survivalHLA matchingGraft functionDeceased donor kidney transplant patientsDeceased donor kidney transplant recipientsOne-year acute rejection ratesDeath-censored graft survivalOne-year acute rejectionOPTN/UNOS registryDonor kidney transplant recipientsAcute rejection ratesKidney transplant patientsKidney transplant recipientsOrgan Sharing databaseKidney transplant survivalDegree of HLAStrong independent predictorUNOS registryAcute rejectionGraft outcomeTransplant recipientsTransplant patientsHLA matchIndependent predictors